Schrodinger (STU:43Z) Debt-to-Revenue : 0.33 (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Schrodinger Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Schrodinger's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €16.0 Mil. Schrodinger's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €96.5 Mil. Schrodinger's annualized Revenue for the quarter that ended in Dec. 2024 was €337.4 Mil. Schrodinger's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 was 0.33.

Schrodinger Debt-to-Revenue Historical Data

The historical data trend for Schrodinger's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Schrodinger Debt-to-Revenue Chart

Schrodinger Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Revenue

Get a 7-Day Free Trial

0.11

0.58

0.64

0.59

0.57

Schrodinger Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Revenue	Get a 7-Day Free Trial															0.43	0.86	0.66	0.85	0.33

Competitive Comparison of Schrodinger's Debt-to-Revenue

For the Health Information Services subindustry, Schrodinger's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Schrodinger's Debt-to-Revenue Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Schrodinger's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Schrodinger's Debt-to-Revenue falls into.

Schrodinger Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Schrodinger's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(16.001	+	96.526)	/	198.2
	=	0.57

Schrodinger's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(16.001	+	96.526)	/	337.372
	=	0.33

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2024) Revenue data.

Schrodinger Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Schrodinger's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Schrodinger Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Schrodinger Inc (STU:43Z) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

SDGR:USA 43Z:Germany

Address

1540 Broadway, 24th Floor, New York, NY, USA, 10036

Website

https://www.schrodinger.com

Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.

Schrodinger Headlines

No Headlines